Major mutations associated with HIV-I integrase inhibitors (INI) resistance are rare in INI-naive patients.However, polymorphisms at positions that may influence the genetic barrier and/or drive the selection ofspecific INI resistance pathways are common in HIV non-B subtypes. The aim was to evaluate the presence ofnatural polymorphisms and/or INI resistance mutations in HIV-1 non-B subtype samples obtained from INInaivepatients living in rural west Cameroon. Thirty-three HIV-1 non-B samples were obtained from INI-naiveAfrican women and, as controls, 15 samples of HIV-1 subtype B were obtained from antiretroviral-naive Italianpatients. The integrase gene was amplified and sequenced using Trugene Core Reagents. Several amino acidpositions in...
We analyzed the gp41 sequences of 80 HIV-infected enfuvirtide-naive individuals who were eligible to...
We evaluated the human immunodeficiency virus type 1 (HIV-1) integrase coding region of the pol gene...
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to ...
Major mutations associated with HIV-I integrase inhibitors (INI) resistance are rare in INI-naive pa...
OBJECTIVES In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI) dolutegravir was rec...
PURPOSE: Integrase (IN) is an enzyme produced by human immunodeficiency virus (HIV)-1 that enables i...
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy...
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy...
Integrase inhibitors (INIs) are a potent option for HIV treatment. Limited data exist on INI resista...
To investigate the prevalence and patterns of major and accessory resistance mutations associated wi...
Previously used as part of salvage therapy, integrase strand transfer inhibitors (INSTIs) have becom...
International audienceHIV-1 group N (HIV-1/N) remains rare and mainly restricted to Cameroon. In thi...
The presence of mutations associated with integrase inhibitor (INI) resistance among INI-naive patie...
Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) ...
Currently the prevalence of HIV-1 infection in Cameroon is 5.1%, CRF02_AG subtype is responsible for...
We analyzed the gp41 sequences of 80 HIV-infected enfuvirtide-naive individuals who were eligible to...
We evaluated the human immunodeficiency virus type 1 (HIV-1) integrase coding region of the pol gene...
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to ...
Major mutations associated with HIV-I integrase inhibitors (INI) resistance are rare in INI-naive pa...
OBJECTIVES In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI) dolutegravir was rec...
PURPOSE: Integrase (IN) is an enzyme produced by human immunodeficiency virus (HIV)-1 that enables i...
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy...
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy...
Integrase inhibitors (INIs) are a potent option for HIV treatment. Limited data exist on INI resista...
To investigate the prevalence and patterns of major and accessory resistance mutations associated wi...
Previously used as part of salvage therapy, integrase strand transfer inhibitors (INSTIs) have becom...
International audienceHIV-1 group N (HIV-1/N) remains rare and mainly restricted to Cameroon. In thi...
The presence of mutations associated with integrase inhibitor (INI) resistance among INI-naive patie...
Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) ...
Currently the prevalence of HIV-1 infection in Cameroon is 5.1%, CRF02_AG subtype is responsible for...
We analyzed the gp41 sequences of 80 HIV-infected enfuvirtide-naive individuals who were eligible to...
We evaluated the human immunodeficiency virus type 1 (HIV-1) integrase coding region of the pol gene...
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to ...